drugset / Trial / NCT03758365

Evaluation of the Vasoconstriction Properties of MC2-01 Cream

NCT03758365

Phase 1 Completed 36 enrolled MC2 Therapeutics
RandomizedParallel-groupSingle-blindTreatment

Summary

The objective of this trial is to compare the vasoconstriction potential

Timeline

Start
2018-11-05
Primary completion
2018-11-23
Completion
2018-11-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcipotriol Small molecule 0.005 %
Comparator Desonide Small molecule 0.05 %
Comparator Hydrocortisone Butyrate Unknown 0.1 %
Comparator Triamcinolone Acetonide Other / unclassified 0.1 %
Comparator betamethasone dipropionate Small molecule 0.05 %
Comparator betamethasone dipropionate Small molecule 0.064 %
Comparator clobetasol propionate Small molecule 0.05 %

Indications